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Abstract
Background: By August 2021, the COVID-19 pandemic has been less severe in sub-Saharan Africa than elsewhere.
In Malawi, there have been three subsequent epidemic waves. We therefore aimed to describe the dynamics of
SARS-CoV-2 exposure in Malawi.
Methods: We measured the seroprevalence of anti-SARS-CoV-2 antibodies amongst randomly selected blood
transfusion donor sera in Malawi from January 2020 to July 2021 using a cross-sectional study design. In a subset,
we also assessed in vitro neutralisation against the original variant (D614G WT) and the Beta variant.
Results: A total of 5085 samples were selected from the blood donor database, of which 4075 (80.1%) were aged
20–49 years. Of the total, 1401 were seropositive. After adjustment for assay characteristics and applying population
weights, seropositivity reached peaks in October 2020 (18.5%) and May 2021 (64.9%) reflecting the first two
epidemic waves. Unlike the first wave, both urban and rural areas had high seropositivity in the second wave,
Balaka (rural, 66.2%, April 2021), Blantyre (urban, 75.6%, May 2021), Lilongwe (urban, 78.0%, May 2021), and Mzuzu
(urban, 74.6%, April 2021). Blantyre and Mzuzu also show indications of the start of a third pandemic wave with
seroprevalence picking up again in July 2021 (Blantyre, 81.7%; Mzuzu, 71.0%). More first wave sera showed in vitro
neutralisation activity against the original variant (78% [7/9]) than the beta variant (22% [2/9]), while more second
wave sera showed neutralisation activity against the beta variant (75% [12/16]) than the original variant (63% [10/
16]).
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Conclusion: The findings confirm extensive SARS-CoV-2 exposure in Malawi over two epidemic waves with likely
poor cross-protection to reinfection from the first on the second wave. The dynamics of SARS-CoV-2 exposure will
therefore need to be taken into account in the formulation of the COVID-19 vaccination policy in Malawi and
across the region. Future studies should use an adequate sample size for the assessment of neutralisation activity
across a panel of SARS-CoV-2 variants of concern/interest to estimate community immunity.
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Background
As of 19 August 2021, more than 209 million people
globally have been infected with the severe acute respira-
tory syndrome (SARS-CoV-2), resulting in more than
4.39 million deaths [1, 2]. The potential risk from SARS-
CoV-2 to Africa was identified early in the global pan-
demic [3]. As the epicentre of transmission moved from
East Asia to West Asia, to Europe, and then to North
America, there was speculation as to the likely impact of
the pandemic on the African continent with its high
rates of infectious diseases including HIV, poverty, and
undernutrition, as well as a fragile healthcare system [3,
4]. However, so far, evidence has shown that the epi-
demiology of the COVID-19 pandemic in sub-Saharan
Africa has been different from the Americas, China, and
Europe [1]. Available seroprevalence data indicate that
SARS-CoV-2 has circulated more widely in African pop-
ulations than can be deduced from the number of re-
ported confirmed cases, hospitalisations, and deaths [5–
8]. This has led to speculations that SARS-CoV-2 could
have circulated longer in sub-Saharan Africa than the
first confirmed cases, but current evidence is limited.
Others have speculated that a high prevalence of circu-
lating seasonal coronaviruses could have induced some
cross-reactive protective immunity [9].
In Malawi, though there were initial plans by the
government in April 2020 to implement a national
lockdown of social and commercial activities, these
were never implemented [10]. As such, unlike other
countries in the region, there were no systematic
lockdowns but only some curfew restrictions. Schools
were officially closed (from 23 March 2020 to 7 Sep-
tember 2020), and many social gathering settings (in-
cluding restaurants and places of worship) voluntarily
closed or had significantly reduced services as a re-
quirement from the government [11]. Malawi closed
its borders and airports from April 2020 to Septem-
ber 2020, with limited essential traffic allowed in and
out of the country [12]. As of 18 August 2021, 58,861
people were confirmed to have been infected by
SARS-CoV-2 in Malawi, resulting in 2012 deaths, and
265,491 people had been fully vaccinated with either
the AstraZeneca (AZD1222) or Jansen vaccines [1].
However, due to limited testing, the true burden of
COVID-19 in Malawi remains unclear.
Blood donor serosurveys are well-used surrogates for
population surveillance of infectious diseases and have
been used together with healthcare worker serosurveys
to estimate and monitor the extent of the SARS-CoV-2
pandemic in several countries [5–8]. Here, we report re-
sults of a national serosurvey using archived serum sam-
ples from blood transfusion donors across Malawi from
January 2020 to July 2021, generated using a World
Health Organization (WHO)-recommended anti-SARS-
CoV-2 receptor-binding domain total antibody assay
with high sensitivity and specificity, supported by SARS-
CoV-2 pseudovirus neutralisation assays to explore vari-
ant specificity. We aimed to estimate the magnitude of
SARS-CoV-2 population exposure, describe the kinetics
of the exposure, approximate the period of SARS-CoV-2
introduction into the population, and determine the viral
variants responsible for the epidemic waves.
Methods
Study setting and population
The Malawi Blood Transfusion Service (MBTS) main-
tains an archive of sera from all blood donations re-
ceived in their Malawi facilities, namely Blantyre
(Odala), Balaka, Lilongwe, and Mzuzu (average of 70,000
annually before the COVID-19 pandemic). All blood do-
nors undergo routine screening through a self-
administered questionnaire, one-on-one assessment, and
a mini-health screening by MBTS staff. Donors meeting
the routine donor ineligibility criteria including age
below 15 or above 65 years; haemoglobin below 12.5 g/
dl; past medical history suggestive of human immuno-
deficiency virus (HIV), hepatitis, or syphilis; and past or
present history of renal, cardiovascular, central nervous
system, and metabolic disorders [13] were excluded. All
donated samples are screened for transfusion transmis-
sible infections (TTI, including HIV). The sera are ar-
chived at − 80 °C and retained by MBTS for up to 5
years for retrospective analysis purposes. MBTS blood
donation services include both static and mobile sites.
Sample selection and processing
Using the MBTS sample archive database, we randomly
selected (using STATA’s gsample command) sera col-
lected from HIV-seronegative individuals aged 15–65
years old, which is the allowable age for blood donation
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in Malawi. Parameters including sex, age, location, and
time were also extracted from the database for analysis.
For Mzuzu, Lilongwe, and Blantyre, selected samples
were only from static urban donation sites. For Balaka, a
largely rural district with smaller total donations, se-
lected samples included donations from both static and
mobile sites, including semi-rural and rural sites. The
sites covered all four defined regions of Malawi: Mzuzu
is the capital of the northern region and the third largest
city, by population, in Malawi (population of 221,272).
Lilongwe is Malawi’s capital city located in the central
region (population of 989,318). Blantyre is the capital of
Malawi’s southern region (population of 800,264). Balaka
is a rural district of 438,379 residents, located in the
eastern region. All population data are from the 2018
Malawi Population and Housing Census [14].
Measurement of SARS-CoV-2 antibodies by enzyme-
linked immunosorbent assay (ELISA)
SARS-CoV-2 receptor-binding domain (RBD) total antibody
ELISA
We used the WHO-recommended WANTAI SARS-
CoV-2 Ab commercial ELISA kit to detect total SARS-
CoV-2 antibodies, following the manufacturer’s instruc-
tions (Beijing Wantai Biological Pharmacy Enterprise
Co., Ltd., China; WS-1096). The sensitivity and specifi-
city of the assay as independently validated are 97%
[95% CI 83.3 to 99.4] and 98% [91.3 to 99.3], respectively
[15]. Specimens giving a ratio of < 0.9 were reported as
negative for this assay, a ratio of > 1.1 were reported as
positive, and a ratio between 0.9 and 1.1 were reported
as borderline. Samples with borderline results were
retested using a confirmatory assay described below.
Confirmatory SARS-CoV-2 spike 2 and nucleoprotein
immunoglobulin G (IgG) antibody ELISA
The COVID-19 IgG RUO commercial ELISA kit
(Omega diagnostics, UK) uses 96-well microtitre plates
pre-coated with purified SARS-CoV-2 spike (S2) and nu-
cleoprotein (N) antigens to detect anti-SARS-CoV-2 IgG
antibodies. This was performed following the manufac-
turer’s instructions as reported previously [5]. The sensi-
tivity and specificity of the assay as independently
validated are 91.1% [95% CI 88.7 to 93.2] and 98.6%
[97.4 to 99.4], respectively. Specimens giving a ratio of <
0.8 were reported as negative for this assay, a ratio of ≥
1.1 were reported as positive, and a ratio between 0.8
and < 1.1 were reported as borderline.
SARS-CoV-2 pseudovirus neutralisation assay
Samples were pre-screened using an in-house SARS-
CoV-2 full-length spike ELISA [16], and only samples
positive for binding antibodies were screened for neu-
tralisation. SARS-CoV-2-pseudotyped lentiviruses were
prepared by co-transfecting the HEK 293T cell line with
either the SARS-CoV-2 original spike (D614G) or the
SARS-CoV-2 beta spike (L18F, D80A, D215G, K417N,
E484K, N501Y, D614G, A701V, 242-244 del) plasmids
in conjunction with a firefly luciferase encoding pNL4
lentivirus backbone plasmid. For the neutralisation assay,
heat-inactivated seropositive serum samples from blood
donors were incubated with the SARS-CoV-2-pseudo-
typed virus for 1 h at 37 °C, 5% CO2. Subsequently, 1 ×
104 HEK 293T cells engineered to overexpress ACE-2
were added and incubated at 37 °C, 5% CO2, for 72 h
upon which the luminescence of the luciferase gene was
measured.
Statistical analysis
We performed statistical analyses and graphical presen-
tations using the R statistical package, version 4.1.0, and
GraphPad Prism v9.1.0 (GraphPad Software, LLC). The
seroprevalence of SARS-CoV-2 antibodies was adjusted
for the independently reported assay sensitivity (97%
[95% CI 83.3 to 99.4]) and specificity (98% [95% CI 91.3
to 99.3]) using the bootComb (v1.0.1) R package [17].
Generalised additive models were used to estimate the
seroprevalence curves from Figs. 1 and 2. A multivari-
able logistic regression model was developed with sex,
age group, location, and time as predictors, to investigate
the demographic factors associated with SARS-CoV-2
antibody positivity. To obtain smooth regression curves,
penalised thin-plate regression splines (as implemented
in the R package mgcv v1.8-35, [18]) were used to model
the effect of time given the non-linear trend in sero-
prevalence over time. Confidence bands for the model
fits were obtained using the estimated standard errors
and a normal approximation for the model national
seroprevalence but were derived using bootstrapping for
the models stratified by location due to the lower sample
sizes. Effects were considered statistically significant
when the p value was less than 0.05.
To compute population weights, we first computed
the proportions of participants by sex and 5-year age
bands (15–19 up to 60–64) for each location and each
month (e.g. proportion of males aged 20–24 in Blantyre
for the month of August 2020). We then used the offi-
cial Malawi census projection figures from the National
Statistics Office [19] for the whole of Malawi for the
mid-year points of 2019, 2020, and 2021 and linearly in-
terpolated the numbers of Malawians of a given sex and
5-year age bands from January 2020 to July 2021 (the
study period). We then calculated the same proportions
of individuals in each sex and 5-year age band for every
month for the census projection data (e.g. proportion of
males aged 20–24 in August 2020). Finally, the popula-
tion weights are obtained by computing the ratio of cen-
sus projection proportions and the MBTS data
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Fig. 1 Overall SARS-CoV-2-adjusted seroprevalence over time superimposed on Malawi national PCR-confirmed COVID-19 cases. Black dots
(together with 95% CI) are estimated seroprevalence at each time point (month), adjusted for assay sensitivity and specificity. The histograms
represent confirmed national COVID-19 cases per month, including asymptomatic and symptomatic cases. The vertical dotted line defines the
transition from 2020 to 2021. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; Ab+, positive for
the detection of anti-SARS-CoV-2 receptor-binding domain (RBD) antibody
Fig. 2 Flexible seroprevalence models. The model fits provide a smoothed estimate of the seroprevalence over time (January 2020 to July 2021)
for each location. A Balaka. B Blantyre. C Mzuzu. D Lilongwe. The orange line is the line of best fit for the empirical data, using a smooth
generalised additive model, along with light orange shading indicating 95% CI. Black dots (together with 95% CI) are estimated seroprevalence at
each time point (months), adjusted for assay sensitivity and specificity. Grey dots (top and bottom of figures) show the individual-level data,
which are either positive (1) or negative (0) for the detection of anti-SARS-CoV-2 receptor-binding domain (RBD) antibody
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proportions (Additional File 1: Table S1). The popula-
tion weights were used to weigh the seroprevalence esti-
mates and to fit the seroprevalence models.
Results
Participant demographics
A total of 5085 blood donor serum samples were se-
lected from the four regional blood transfusion centres
that were collected between January 2020 and July 2021.
These included 1208 from Mzuzu (northern region),
1328 from Lilongwe (central region), 1198 from Balaka
(eastern region), and 1351 from Blantyre (southern re-
gion) (Table 1). Compared with the 2018 Malawi Popu-
lation and Housing Census [14], by the nature of the
demographic of blood donors in Malawi, participants
were more commonly male (72.6% in our study versus
48.5% in the census) and had more persons aged 20 to
49 years (80.1% versus 35.4%).
Overall SARS-CoV-2 antibody seroprevalence
Of the 5085 samples, 1380 were positive for anti-SARS-
CoV-2 RBD total antibody and 32 were borderline. After
re-running the borderline samples using the separate
commercial confirmatory ELISA as stated in the
methods, 21 of the 32 were positive for anti-SARS-CoV-
2 S2 and N IgG antibody, resulting in a total of 1401
anti-SARS-CoV-2 antibody-positive samples.
As part of quality control, we randomly selected 76
samples that were positive on the primary SARS-CoV-2
ELISA and retested them using the second ELISA target-
ing S2 and NP IgG. Seventy-one of the 76 samples were
positive on the second ELISA, representing a concord-
ance of 93.4% [95% CI 85.3 to 97.8]. We also used a re-
cently published in-house ELISA [16] that targets
binding antibodies against RBD of the original SARS-
CoV-2 variant on a subset of 36 serum samples selected
from the seroprevalence peaks. The concordance be-
tween the Wantai and in-house ELISA was 100%.
In an unweighted multivariable logistic regression
model, the proportion of seropositive samples did not
vary significantly by sex (p = 0.56) or age (p > 0.10 for
all age groups using those 15–19 years old as a refer-
ence) but did vary geographically (p < 0.001 for all loca-
tions using Balaka as a reference) (Table 2). Amongst
the urban areas, Lilongwe had lower seroprevalence than
Mzuzu and Blantyre. As of July 2021, the overall
population-weighted and assay characteristics (sensitivity
and specificity)-adjusted seroprevalence was 70.2% (95%
CI 62.2 to 81.6%) (Fig. 1).
Temporal trend of SARS-CoV-2 seroprevalence
The first PCR-confirmed case of COVID-19 identified
by Malawi’s national surveillance system was on 2 April
2020, with the first peak of the national COVID-19 cases
being July 2020 (2813 cases) and subsequently a second
peak in January 2021 (17,380 cases) (Fig. 1). In this
study, the first seropositive samples were observed in
February 2020 in Balaka (1 sample) and March 2020 in
Blantyre (2 samples) (Fig. 2). Population-weighted and
assay characteristic-adjusted seroprevalence estimates in-
creased with time, with two distinct waves that followed
the same temporal trend as the reported national
COVID-19 cases (Fig. 1). When aggregating serum sam-
ples from all locations, population-weighted assay
characteristic-adjusted seropositivity was highest in Oc-
tober 2020 (18.5%), May 2021 (64.9%), and July 2021
70.2%) reflecting the two epidemic waves and the be-
ginning of a third epidemic wave (Fig. 1). However,
there were differences in the temporal trend in sero-
prevalence according to location (Fig. 2). Balaka had a
0% weighted and adjusted seroprevalence from Janu-
ary to October 2020, subsequently increasing from 3.8
to 63.5% between December 2020 and July 2021,
peaking at 66.2% in April 2021. The peak weighted
and adjusted seroprevalence in the first wave was Oc-
tober 2020 in Blantyre (20.6%), November 2020 in
Lilongwe (13.1%), and October 2020 in Mzuzu
(25.2%). Seroprevalence bubble plots at six periods in
time demonstrated widespread exposure amongst
blood donors across the country from January 2021
compared to the earlier periods (Fig. 3).
Table 1 Participant demographics and site characteristics
Balaka Blantyre Lilongwe Mzuzu Overall
Region Eastern Southern Central Northern –
Rural/urban Rural Urban Urban Urban –
Pop density (persons/km2)j 205 3334 2455 1516 –
Sampling frame All locations Static Static Static –
Gender, % male (N) 68.9% (825) 77.6% (1049) 64.5% (856) 79.6% (962) 72.6% (3692)
Age, median (IQR) 20.8 (19.7–24.9) 26.9 (21.9–34.1) 30.1 (23.8–37.9) 24.6 (20.2–31.6) 25.0 (20.7–33.2)
Sample size 1198 1351 1328 1208 5085
IQR interquartile range, km kilometre
jSource: 2018 Malawi Population and Housing Census main report
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Table 2 SARS-CoV-2 anti-RBD total antibody seroprevalence in blood donors by participant characteristics and location
Variable Category Sample size Seropositive (frequency) Unadjusted (%) Estimate SE z value p value
Intercept − 6.12 0.76 − 8.11 < 0.001
Gender Female 1393 407 29.2% Ref Ref Ref Ref
Male 3692 994 26.9% 0.05 0.09 0.58 0.56
Age group 15–19§ 912 265 29.1% Ref Ref Ref Ref
20–29 2465 684 27.7% − 0.04 0.11 − 0.32 0.75
30–39 1068 284 26.6% − 0.01 0.13 − 0.06 0.95
40–49 596 154 25.8% 0.16 0.15 1.04 0.3
50+ 44 14 31.8% 0.2 0.38 0.53 0.6
Location Balakaφ 1198 254 21.2% Ref Ref Ref Ref
Blantyre 1351 416 30.8% 0.77 0.13 5.92 < 0.001*
Lilongwe 1328 345 26.0% 0.6 0.13 4.56 < 0.001*
Mzuzu 1208 386 32.0% 0.86 0.13 6.41 < 0.001*
This is an unweighted multivariable logistic regression model with sex, age group, location, and time as predictors
§Recruitment limited to blood donors ≥15 years of age
*Significant based on p value < 0.05
φBalaka was used as a reference as it is the only Malawi Blood Transfusion Service (MBTS) static site that directly covers the rural area
Fig. 3 Seroprevalence bubble plot for the overall seroprevalence at three snapshots in time. The size of the bubble is proportional to the
prevalence of samples positive for anti-SARS-CoV-2 receptor-binding domain (RBD) antibody within each location
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Estimating predominant SARS-CoV-2 variants driving
seroprevalence
Sequencing data from Malawi deposited on Global Ini-
tiative on Sharing Avian Influenza Data (GISAID) show
that the beta variant was the most dominant variant
(96% [152/159]) identified from the samples collected in
January 2021 [20], suggesting that Malawi’s second wave
was driven by this variant. Following previous observa-
tions that antibodies elicited by the original variant
(D614G WT) are less potent against the beta variant [16,
21], we reasoned that differential neutralisation potency
by SARS-CoV-2 antibodies could be used to estimate
the predominance of specific variants driving seropreva-
lence. We therefore measured pseudovirus neutralisation
against the original variant and the beta variant in ran-
domly selected seropositive sera collected from June to
October 2020 (wave 1) compared to those collected in
February 2021 (wave 2). Wave 1 sera were more potent
against the original variant than the beta variant, while
wave 2 sera were relatively more potent against the beta
variant than the original variant (Fig. 4A, B). About 78%
(7/9) of the wave 1 sera had neutralising activity against
the original variant, but only 22% (2/9) of the wave 1
sera returned neutralising activity against the beta vari-
ant (Fig. 4B), while 75% (12/16) of the wave 2 sera had
neutralising activity against the beta variant and 63%
(10/16) of the wave 2 sera returned neutralising activity
against the original variant (Fig. 4B). Furthermore, 19%
(6/31) of the wave 2 sera showed no neutralisation
against the beta variant or the original variant (Fig. 4A).
Collectively, these results support the existing genomic
sequencing evidence that Malawi’s second SARS-CoV-2
epidemic wave was driven by the beta variant and also
indicates potential poor cross-protection from wave 1
infection (original variant) on wave 2 infection (beta
variant).
Discussion
Our study provides important insights into the dynamics
of the COVID-19 epidemic in both urban and rural
Malawi, with relevance to the southern African region.
The seroprevalence estimates from this serosurvey are
very high compared to the reported national surveillance
figures for confirmed asymptomatic and symptomatic
cases, but they do reflect the emergence and magnitude
of the first and second COVID-19 epidemic waves in
Malawi. They also provide evidence against the specula-
tion that SARS-CoV-2 had been circulating more widely
in Malawi before the first detected case in April 2020 or
that circulation of endemic coronaviruses [9] had
Fig. 4 Neutralisation of viral variants using the sera from the first and second epidemic waves. Anti-RBD seropositive sera from the SARS-CoV-2
epidemic waves 1 and 2 were subjected to a SARS-CoV-2 pseudovirus neutralisation assay. A Correlation of SARS-CoV-2 antibody neutralisation
potency against D614G WT and beta variant. B Proportion of wave 1 or wave 2 sera with neutralisation activity against D614G WT or beta variant.
The threshold of detection for the neutralisation assay is ID50 > 20. RBD, receptor-binding domain
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generated cross-reactive antibody responses. Data from
pseudovirus neutralisation assays suggests that the sec-
ond wave was predominantly driven by the beta variant
and highlights poor cross-protection from the first wave
on the second wave.
We report a high seroprevalence of 51.5% nationally in
February 2021, mirroring the upsurge in confirmed
COVID-19 cases, hospitalisations, and death in Malawi
experienced during this period [1, 4]. This is consistent
with a study in South African blood donors that re-
ported seroprevalence rates ranging from 31.8 to 62.5%
in January 2021 [22]. So far, the epidemic trajectory in
Malawi as determined by the national confirmed
COVID-19 cases, deaths, and hospitalisations has paral-
leled the epidemic trajectory in South Africa [1]. This is
likely due to frequent human migration between the two
countries, specifically in the last 12 months during which
there has been an influx of groups of returning residents
from South Africa to Malawi. This movement of people
coincided with rapid surges in COVID-19 cases in the
first and second epidemic waves in Malawi [23]. These
findings support the need for a consolidated and stan-
dardised regional public health effort in Southern Africa
to effectively reduce the risk of further epidemic waves
across the region.
Genomic surveillance data from Malawi and South Af-
rica suggests that this high seroprevalence in the second
wave is, at least in part, driven by the emergence of the
beta variant [20]. In agreement, our neutralisation data
showed that a higher proportion of sera collected from
the second wave (February 2021) had neutralising activ-
ity against the beta variant than sera from the first wave
(June to October 2020), indicating antibody responses
driven by infection with the beta variant rather than the
original variant (D614G WT). This is consistent with
previous studies showing that homologous convalescent
sera retain higher in vitro neutralisation potency than
heterologous convalescent sera against the infecting
virus [16, 21, 24, 25]. It is also noteworthy that 19% of
the second wave sera that were positive for antibodies to
the SARS-CoV-2 RBD showed no neutralisation against
the beta variant or D614G WT, highlighting a discon-
nect between qualitative antibody detection and func-
tional activity. This discordance is likely due to low anti-
RBD antibody titres as they have been shown to be asso-
ciated with poor in vitro neutralisation [21]. It could also
be due to infections from other variants of interest/
concern.
The temporal kinetics of the SARS-CoV-2 seropreva-
lence in this serosurvey suggests that the first epidemic
wave was largely confined to urban areas. This differs
from the second wave, which was more rapid not only in
its growth but also in its geographic spread, as shown by
the high seroprevalence even in the rural areas. This is
consistent with national surveillance reports showing
that confirmed COVID-19 cases in the first wave were
primarily from the three major cities, Blantyre, Lilongwe,
and Mzuzu, but in the second wave, there was an in-
crease in reported cases in rural areas [26]. Considering
that no vaccine was being administered in Malawi be-
tween December 2020 and 11 March 2021, the poor
cross-protection of first wave sera on the beta variant
could in part have contributed to the rapid emergence
and spread of this variant in the population. On the
other hand, in other settings, high seroprevalence is be-
ing driven by high vaccination coverage, but in Malawi,
as of July 2021, the coverage was less than 2% of the eli-
gible population; hence, it is highly unlikely that the high
seroprevalence was driven by vaccination.
This study has considerable strengths, including con-
sistent monthly sampling, use of well-validated assays,
and national geographical representation. There are
however some important limitations. First, inherent in
using a blood donor sampling frame is that they are not
representative of the general population. To mitigate
this, the seroprevalence estimates were weighted for
population structure based on the official Malawi 2018
Population and Housing Census projection data for the
study period. However, we were unable to evaluate the
association between the behaviour of blood donors and
risk of acquisition to SARS-CoV-2 infection, as this may
bias the measured results away from the true population
seropositivity. Population-based serosurvey is the ideal,
and these could be highly recommended for future stud-
ies. Second, in some individuals, SARS-CoV-2 antibodies
wane over time to undetectable levels leading to false
negatives, especially in those who had asymptomatic
COVID-19 [27, 28]. Therefore, the seroprevalence esti-
mates are likely an underestimate of the cumulative ex-
posure within this sampled population. However, the
sampling bias and waning of antibody levels are unlikely
to substantially alter the temporal trends reported in this
study.
Conclusions
We report a dramatic rise in SARS-CoV-2 seropreva-
lence from 18.5% in October 2020 to 64.9% in May 2021
in healthy blood donors as Malawi experienced the first
and second COVID-19 epidemic waves, likely driven ini-
tially by the original variant (D614G WT) and then the
beta variant [29–31]. The dynamics of SARS-CoV-2 ex-
posure will therefore need to be taken into account in
the formulation of the COVID-19 vaccination policy in
Malawi and across the region. We recommend that fu-
ture studies should include an adequate sample size to
assess neutralisation activity across a larger panel of vari-
ants of concern/interest as a surrogate of protective im-
munity at a population level.
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